Key Insights

Highlights

Treatment Research

2 treatments under study, led by Homologous Blood Transfusion

Research Leaders

5 sponsors active, led by Laboratorio Antidoping FMSI

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03548766Phase 3Unknown

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

Showing all 1 trials

Research Network

Common Treatments

  • Homologous Blood Transfusion1
  • Autologous Blood Transfusion1

Active Sponsors

  • Laboratorio Antidoping FMSI1
  • Anti-Doping Lab Qatar1
  • Sidra Medicine1
  • World Anti-Doping Agency1
  • Hamad Medical Corporation1

Top Investigators

Related Conditions

  • Blood Transfusion Autologous1
  • Blood Doping1
  • Blood Disease1

Activity Timeline